Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Cepheid's share price for the quarter that ended in Sep. 2016 was €46.55. Cepheid's Shares Outstanding (EOP) for the quarter that ended in Sep. 2016 was 73.0 Mil. Therefore, Cepheid's market cap for the quarter that ended in Sep. 2016 was €3,398.5 Mil.
Cepheid's quarterly market cap
declined
from Mar. 2016 (€2,074.0 Mil) to Jun. 2016 (€2,005.8 Mil) but then
increased
from Jun. 2016 (€2,005.8 Mil) to Sep. 2016 (€3,398.5 Mil).
Cepheid's annual market cap
increased
from Dec. 2013 (€2,282.2 Mil) to Dec. 2014 (€3,095.7 Mil) but then
declined
from Dec. 2014 (€3,095.7 Mil) to Dec. 2015 (€2,377.4 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cepheid's Enterprise Value for Today is €3,453.3 Mil.
Cepheid Market Cap Historical Data
The historical data trend for Cepheid's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Cepheid's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cepheid's Market Cap Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cepheid's Market Cap distribution charts can be found below:
* The bar in red indicates where Cepheid's Market Cap falls into.
Cepheid Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Cepheid's Market Cap for the fiscal year that ended in Dec. 2015 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cepheid (FRA:XEP) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Cepheid Market Cap Related Terms
Thank you for viewing the detailed overview of Cepheid's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Cepheid was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's product portfolio consists of tests, reagents and systems for the clinical and non-clinical markets. The Company's two systems are the GeneXpert and SmartCycler. The GeneXpert system, offers services in the clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. Company faces competition from a number of companies that offer products to its target markets. Company has patents covering technologies of its own and has licensed technologies from others. In addition to patents, it rely on a combination of trade secrets, copyright and trademark laws, nondisclosure agreements, licenses and other contractual provisions and technical measures to maintain and develop its competitive position with respect to intellectual property. In the Clinical market, its products are regulated as medical device products by the FDA and comparable agencies in other countries. For the Non-Clinical market, all of its products are being produced under ISO 13485 and Quality System Regulations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:XEP has been successfully added to your 